2 Mar 2011
Product in Phase IIB

Compound available for licensing and/or development partnership.  This product has been designated an orphan drug by the FDA for the treatment of Scleroderma.  Additional patent is pending for the treatment of Rheumatoid Arthritis.

Return to Press Releases